Consensus Ocugen, Inc. Börse Stuttgart

Stocks

2H51

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 12:22:00 2026-08-03 EDT			5-day change	1st Jan Change
1.099 ^EUR	+2.33%		+1.13%	-15.76%

07-29	Ocugen Receives RMAT Designation for OCU410 for Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI
07-13	Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa	CI

Evolution of the Average Target: Ocugen, Inc.

Evolution of the Target Price: Ocugen, Inc.

Changes in Analyst Recommendations: Ocugen, Inc.

9cb.Ijx-05I0cZh8eS3AGhNXb7JuyaBzdp3CeMwPyn-Zodg.UA0Zh_17HfZEOx2FLiBiFss55PkmOOnzNo1IsBzq65BTCiyp5FsrywwoaA~3efa31f772c1e741bd7760d3ac5e1bbc

Analysts' recommendations: Ocugen, Inc.

04-10	Ocugen, Inc. Announces Modifier Gene Therapy Delivers 46% Lesion Reduction in Age-Related Macular Degeneration	CI
03-17	Canaccord Genuity Initiates Ocugen at Buy With $12 Price Target	MT
03-11	Top Midday Gainers	MT
03-11	Oppenheimer Initiates Ocugen at Outperform With $10 Price Target	MT
25-03-06	Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating	MT
24-04-22	Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	MT
24-04-22	Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	MT
24-01-24	HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating	MT
23-08-31	Cantor Fitzgerald Adjusts Ocugen's Price Target to $2 From $2.50, Keeps Overweight Rating	MT
23-05-08	Chardan Research Raises Ocugen's Price Target to $4 From $3.50, Buy Rating Kept	MT
23-03-01	Chardan Upgrades Ocugen to Buy From Neutral, Citing Recent Sell-Off	MT
23-03-01	Mizuho Adjusts Price Target on Ocugen to $3 From $5, Maintains Buy Rating	MT
22-08-23	Mizuho Securities Starts Ocugen at Buy With $5 Price Target	MT
22-08-15	HC Wainwright Adjusts Ocugen's Price Target to $6 from $7, Maintains Buy Rating	MT
22-06-15	Roth Capital Reinstates Ocugen at Buy with $8 Price Target	MT
22-06-02	Cantor Fitzgerald Starts Ocugen at Overweight With $4.50 Price Target	MT
22-05-09	Chardan Trims Ocugen's Price Targe to $3.50 From $4, Maintains Neutral Rating	MT
22-05-09	Chardan Research Adjusts Ocugen's Price Target to $3.50 From $4, Maintains Neutral Rating	MT
22-02-28	HC Wainwright Adjusts Ocugen's Price Target to $8 from $10, Maintains Buy Rating	MT
21-06-14	Analyst recommendations: Alliant Energy, Ally Financial, Alphabet, HSBC, Honest...
21-06-11	OCUGEN : Chardan Adjusts Ocugen PT to $4.50 From $8, Maintains Neutral Rating	MT
21-06-11	OCUGEN : Cantor Fitzgerald Adjusts Ocugen PT to $4 From $11, Maintains Neutral Rating	MT
21-06-11	OCUGEN : HC Wainwright Adjusts Ocugen's Price Target to $10 From $12, Maintains Buy Rating	MT
21-06-11	OCUGEN : Roth Capital Cuts Ocugen to Neutral From Buy, Price Target to $6 From $10	MT
21-05-10	OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LONZA GROUP AG					+21.08%
	REVOLUTION MEDICINES, INC.					+10.38%
	IQVIA HOLDINGS INC.					+16.14%
	BEONE MEDICINES AG					+31.53%
	CELLTRION, INC.					+42.05%
	MEDPACE HOLDINGS, INC.					+0.82%
	ASCENDIS PHARMA A/S					+24.82%
	EUROFINS SCIENTIFIC SE					+6.41%
	ICON PUBLIC LIMITED COMPANY					+13.45%
	Average					+18.52%
	Weighted average by Cap.					+20.33%